- Joined
- Apr 11, 2009
- Messages
- 1,628
- Reaction score
- 1,710
As a diagnostic wielder of radiation, this is what I read as well.My understanding of rt in the oligometastatic setting is to theoretically kill all of the remaining cancer. The proposition here is not that it makes new Mets. It's that it releases a growth ligand that could make subclinical disease become clinical. This would happen anyway if there is subclinical disease, rt or no. Hence, what does this have to do with anything? Sbrt for oligomets doesn't work if there's subclinical disease elsewhere, not because it induces new Mets out of the ether.
Maybe it’s not a ligand at all. Maybe radiation is immune suppressive and the down regulation of the immune system allows suppressed Mets to thrive?
Hence let’s give immune therapy and RT at the same time!